The Quantellect read.As of Nov 19, 2026, 11 active firms cover Trevi Therapeutics Inc: 11 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $16.00 to $36.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $24.36 sits 80% above the current $13.53. The rating mix has stayed broadly stable, with Buy-side ratings easing from 12 to 11 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.16 next quarter toward $-0.60 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy11100%
Neutral00%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$24.36
+80.1% upside
Average target across 11 active firms as of Nov 19, 2026 vs $13.53 current
Highest Target$36.00
Average Target$24.36
Lowest Target$16.00
Detailed analyst forecasts for TRVI
Showing 1–11 of 11 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 11 of 11 active firms rate TRVI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TRVI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.17 – $-0.15 · 2 analysts · +78% YoY
Next period, 2 analysts expect Trevi Therapeutics Inc to earn $-0.16 a share (range $-0.17 – $-0.15), versus $-0.09 a year earlier. Full-year consensus is $-0.50, growing to $-0.60 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Trevi Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TRVI.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$31.00+129.1% to target
Overall win rate
49%
+ Follow
#2
Serge Belanger
Needham · Rank #129
Buy
$23.00+70.0% to target
Overall win rate
46%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #132
Buy
$30.00+121.7% to target
Overall win rate
44%
+ Follow
#4
Oren Livnat
HC Wainwright & Co. · Rank #217
Buy
$12.50-7.6% to target
Overall win rate
54%
+ Follow
#5
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$24.00+77.4% to target
Overall win rate
38%
+ Follow
TRVI stock forecast FAQ
What is TRVI's average 12-month price target?+
The 11 active firms with a live target average $24.36 for Trevi Therapeutics Inc over the next 12 months, ranging from a $36.00 high to a $16.00 low, as of Nov 19, 2026.
Is TRVI stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 11 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TRVI?+
The Street-high target is $36.00 (BMO Capital), and the Street-low is $16.00 (Leerink Partners). The average of all 11 active-firm targets is $24.36.
How many active Wall Street firms cover TRVI?+
11 active firms have a recognized rating on Trevi Therapeutics Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TRVI?+
Among analysts who currently cover TRVI, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $31.00 target.
What is Trevi Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.17 – $-0.15) across 2 analysts. Full-year EPS is projected at $-0.50, rising to $-0.60 the following year.
How much revenue is Trevi Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TRVI lately?+
As of Nov 19, 2026, 11 of 11 active firms rate TRVI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TRVI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.